68,551 Shares in Boston Scientific Corporation $BSX Purchased by Osmosis Investment Management UK Ltd

Osmosis Investment Management UK Ltd acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 68,551 shares of the medical equipment provider’s stock, valued at approximately $2,926,000.

A number of other hedge funds have also made changes to their positions in the company. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter worth approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the 1st quarter worth $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Needham & Company LLC dropped their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. TD Cowen decreased their target price on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a report on Friday, June 12th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Up 0.0%

NYSE BSX opened at $50.39 on Monday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $46.34 and its 200-day simple moving average is $57.62. The firm has a market cap of $73.03 billion, a PE ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.